Drug Database · Clinicians

Iron sucrose

Also known as: iron saccharate (chemical description) · ferric hydroxide sucrose complex (chemical description)

Brands (61) Irsuc, Bliron, Eoferon…Show all

US brand (reference label): Venofer; not a Philippine-registered brand.

Parenteral Iron Replacement US FDA class
Anti-anemic preparation; Anti-anemia; and others PH FDA category

Rx · Prescription drug75 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID b998ef36-81fa-40a1-9cd1-6d6156f91564, version date March 1, 2026 (Venofer · American Regent, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Venofer is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD).
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Venofer is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). Venofer is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). (1)

Contraindications

4 CONTRAINDICATIONS Known hypersensitivity to Venofer. Known hypersensitivity to Venofer (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Venofer must only be administered intravenously either by slow injection or by infusion. The dosage of Venofer is expressed in mg of elemental iron. Each mL contains 20 mg of elemental iron. Population Dose Adult patients Hemodialysis Dependent-Chronic Kidney Disease (HDD-CKD) (2.2)
  • 100 mg slow intravenous injection or infusion Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) (2.3)
  • 200 mg slow intravenous injection or infusion Peritoneal Dialysis Dependent-Chronic Kidney Disease (PDD-CKD) (2.4)
  • 300 mg or 400 mg intravenous infusion Pediatric patients HDD-CKD (2.5), PDD-CKD or NDD-CKD (2.6)
  • 0.5 mg/kg slow intravenous injection or infusion
2.1 Mode of Administration

2.1 Mode of Administration Administer Venofer only intravenously by slow injection or by infusion. The dosage of Venofer is expressed in mg of elemental iron. Each mL contains 20 mg of elemental iron.

2.2 Adult Patients with Hemodialysis Dependent-Chronic Kidney Disease (HDD-CKD)

2.2 Adult Patients with Hemodialysis Dependent-Chronic Kidney Disease (HDD-CKD) Administer Venofer 100 mg undiluted as a slow intravenous injection over 2 to 5 minutes, or as an infusion of 100 mg diluted in a maximum of 100 mL of 0.9% NaCl over a period of at least 15 minutes, per consecutive hemodialysis session [see How Supplied/Storage and Handling (16.2).] Administer Venofer early during the dialysis session (generally within the first hour). The usual total treatment course of Venofer is 1000 mg.

Venofer treatment may be repeated if iron deficiency reoccurs.

2.3 Adult Patients with Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD)

2.3 Adult Patients with Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) Administer Venofer 200 mg undiluted as a slow intravenous injection over 2 to 5 minutes or as an infusion of 200 mg in a maximum of 100 mL of 0.9% NaCl over a period of 15 minutes. Administer on 5 different occasions over a 14 day period. There is limited experience with administration of an infusion of 500 mg of Venofer, diluted in a maximum of 250 mL of 0.9% NaCl, over a period of 3.5 to 4 hours on Day 1 and Day 14 [see How Supplied/Storage and Handling (16.2).] Venofer treatment may be repeated if iron deficiency reoccurs.

2.4 Adult Patients with Peritoneal Dialysis Dependent-Chronic Kidney Disease (PDD-CKD)

2.4 Adult Patients with Peritoneal Dialysis Dependent-Chronic Kidney Disease (PDD-CKD) Administer Venofer in 3 divided doses, given by slow intravenous infusion, within a 28 day period: 2 infusions each of 300 mg over 1.5 hours 14 days apart followed by one 400 mg infusion over 2.5 hours 14 days later. Dilute Venofer in a maximum of 250 mL of 0.9% NaCl [see How Supplied/Storage and Handling (16.2).] Venofer treatment may be repeated if iron deficiency reoccurs.

2.5 Pediatric Patients (2 Years of Age and Older) with HDD-CKD for Iron Maintenance Treatment

2.5 Pediatric Patients (2 Years of Age and Older) with HDD-CKD for Iron Maintenance Treatment For iron maintenance treatment: Administer Venofer at a dose of 0.5 mg/kg, not to exceed 100 mg per dose, every two weeks for 12 weeks given undiluted by slow intravenous injection over 5 minutes or diluted in 0.9% NaCl at a concentration of 1 to 2 mg/mL and administered over 5 to 60 minutes. Do not dilute to concentrations below 1 mg/mL [see How Supplied/Storage and Handling [16.2].) Venofer treatment may be repeated if necessary.

The dosing for iron replacement treatment in pediatric patients with HDD-CKD has not been established.

2.6 Pediatric Patients (2 Years of Age and Older) with NDD-CKD

2.6 Pediatric Patients (2 Years of Age and Older) with NDD-CKD or PDD-CKD who are on Erythropoietin Therapy for Iron Maintenance Treatment For iron maintenance treatment: Administer Venofer at a dose of 0.5 mg/kg, not to exceed 100 mg per dose, every four weeks for 12 weeks given undiluted by slow intravenous injection over 5 minutes or diluted in 0.9% NaCl at a concentration of 1 to 2 mg/mL and administered over 5 to 60 minutes. Do not dilute to concentrations below 1 mg/mL [see How Supplied/Storage and Handling (16.2).] Venofer treatment may be repeated if necessary.

The dosing for iron replacement treatment in pediatric patients with NDD-CKD or PDD-CKD has not been established.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration)

2.2 Adult Patients with Hemodialysis Dependent-Chronic Kidney Disease (HDD-CKD) Administer Venofer 100 mg undiluted as a slow intravenous injection over 2 to 5 minutes, or as an infusion of 100 mg diluted in a maximum of 100 mL of 0.9% NaCl over a period of at least 15 minutes, per consecutive hemodialysis session [see How Supplied/Storage and Handling (16.2).] Administer Venofer early during the dialysis session (generally within the first hour). The usual total treatment course of Venofer is 1000 mg. Venofer treatment may be repeated if iron deficiency reoccurs.

2.3 Adult Patients with Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) Administer Venofer 200 mg undiluted as a slow intravenous injection over 2 to 5 minutes or as an infusion of 200 mg in a maximum of 100 mL of 0.9% NaCl over a period of 15 minutes. Administer on 5 different occasions over a 14 day period. There is limited experience with administration of an infusion of 500 mg of Venofer, diluted in a maximum of 250 mL of 0.9% NaCl, over a period of 3.5 to 4 hours on Day 1 and Day 14 [see How Supplied/Storage and Handling (16.2).] Venofer treatment may be repeated if iron deficiency reoccurs.

2.4 Adult Patients with Peritoneal Dialysis Dependent-Chronic Kidney Disease (PDD-CKD) Administer Venofer in 3 divided doses, given by slow intravenous infusion, within a 28 day period: 2 infusions each of 300 mg over 1.5 hours 14 days apart followed by one 400 mg infusion over 2.5 hours 14 days later. Dilute Venofer in a maximum of 250 mL of 0.9% NaCl [see How Supplied/Storage and Handling (16.2).] Venofer treatment may be repeated if iron deficiency reoccurs.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness of Venofer for iron replacement treatment in pediatric patients with dialysis-dependent or non-dialysis-dependent CKD have not been established. Safety and effectiveness of Venofer for iron maintenance treatment in pediatric patients 2 years of age and older with dialysis-dependent or non-dialysis-dependent CKD receiving erythropoietin therapy were studied.

Venofer at doses of 0.5 mg/kg, 1 mg/kg, and 2 mg/kg was administered. All three doses maintained hemoglobin between 10.5 g/dL and 14.0 g/dL in about 50% of subjects over the 12-week treatment period with stable EPO dosing [see Clinical Studies (14.7)]. Venofer has not been studied in patients younger than 2 years of age.

In a country where Venofer is available for use in children, at a single site, five premature infants (weight less than 1,250 g) developed necrotizing enterocolitis and two of the five died during or following a period when they received Venofer, several other medications and erythropoietin. Necrotizing enterocolitis may be a complication of prematurity in very low birth weight infants.

No causal relationship to Venofer or any other drugs could be established.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the 1,051 patients in two post-marketing safety studies of Venofer, 40% were 65 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

In general, dose administration to an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Administration

2.1 Mode of Administration Administer Venofer only intravenously by slow injection or by infusion. The dosage of Venofer is expressed in mg of elemental iron. Each mL contains 20 mg of elemental iron.

US FDA label

Dosage forms

Philippines

  • ) solution for injection: 20 mg/mL ( 100 mg/5 mL, 20 mg/mL (100 mg/5 mL, 20 mg/mL(100 Mg/5 mL
  • Solution for injection: 20 mg/mL, 100 mg/5 mL
  • Solution for intravenous injection: 20 mg/mL
  • ) concentrate for solution for injection: 20 mg/mL (100 mg/5 mL
  • ) solution for i.v. injection: 20 mg/mL (100 mg/5 mL
  • ) solution for iv injection: 20 mg/mL (100 mg/5 mL
  • ) lyophilized powder for injection: 20 mg/mL (100 mg/5 mL
  • ) solution: 20 mg/mL (100 mg/5 mL
  • ) solution for intravenous infusion: 20 mg/mL (100 mg/5 mL
  • Elemental iron) solution for injection: 363.64 mg/mL (equivalent to 20 mg

Registered products in the Philippines

75 products registered with the Food and Drug Administration (FDA) Philippines list Iron sucrose as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products75
Philippine FDA-registered products for Iron sucrose
Package insert
AeferoseIron (as Iron sucrose)
20 mg/mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 5’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India
Dynasty PharmaceuticalsImporter: Ambica International CorporationTrader: Unosource Pharma Limited
DRP-10886-01
Dec 8, 2037
AnemaIron Sucrose
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I Clear Colorless Glass Ampoule x 5mL (Box of 5's)
Rx
Gland Pharma LimitedIndia
Corbridge Group Phils. Inc.Importer: Biocare Lifesciences, Inc.
DRP-5540
Jul 8, 2030
AnemlesIron (as Iron Sucrose)
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
Afree Pharmaceutical Distribution Corp.
DRP-13888
May 11, 2028
BiferronIron (as Iron Sucrose)
20 mg/mL (100 mg/5 mL) SolutionAmber Type I Glass Ampoule with Blue Ring on Neck x 5 mL (Box of 5’s)
Rx
Kwality Pharmaceuticals Ltd.India
Pharma-Surrey International, Inc.
DRP-16388
Feb 26, 2030
BioroseIron (as Iron Sucrose)
100 mg/5 mL Solution for Injection (I.V.)USP Type I Amber Glass Ampoule x 5 mL (Box of 5's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Ambica International Corporation
DRP-7844
Jan 26, 2028
BlironIron (as Iron Sucrose)
20 mg/ mL (100 mg/ 5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp.
DRP-13888-03
May 11, 2028
BlironIron (as Ferric Hydroxide Sucrose Complex)
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)5mL USP Type I amber glass ampoule (Box of 5's)
Rx
Alwin DMD PharmaceuticalsIndia
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-7111
Mar 17, 2027
ClferIron (as Ferric Hydroxide Sucrose Complex)
20 mg/mL (100mg/5mL) Solution for Injection (IV)5mL USP Type I amber glass ampoule (Box of 5's)
Rx
Alwin DMD PharmaceuticalsIndia
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-7111-05
Mar 17, 2027
DubesoneIron (as Iron sucrose)
20 mg/mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 5’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III - Injectables)India
Ambica International CorporationTrader: Unosource Pharma Limited
DRP-10885
Dec 29, 2031
EnciferIron Sucrose
20 mg/mL Solution for Injection (IV)5 mL USP Type I Transparent Flint Glass Ampoule (Box of 5's)
Rx
Emcure Pharmaceuticals LimitedIndia
Macropharma Corporation
DR-XY33701
Aug 2, 2029
EoferonIron (as Ferric Hydroxide Sucrose Complex)
20 mg / mL (100 mg / 5 ml) Solution for Injection (IV)5 mL Amber Glass Ampoule (Box of 5’s)
Rx
Zee Laboratories LimitedHimachal Pradesh India
Eon Pharmatek Inc.
DRP-15056
Oct 5, 2032
EoferonIron (as Ferric Hydroxide Sucrose Complex)
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)5 mL Amber Glass Ampoule (Box of 5's)
Rx
Zee Laboratories LimitedIndia
Eon Pharmatek Inc.
DR-XY48363
Oct 5, 2027
EufercrosIron (as Iron Sucrose)
100 mg/5 mL Solution for Injection (I.V.)USP Type I Amber Glass Ampoule x 5 mL (Box of 1 PVC Tray x 5's)
Rx
Swiss Parenterals Ltd. (Block-B)India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-7844-02
Jan 26, 2028
EvaferIron sucrose
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I Clear Glass Ampoule x 5 mL in a Clear PVC Plastic Tray x 5's (Box of 5's)
Rx
Samrudh Pharmaceuticals Pvt. Ltd.India
Medethix, Inc.Importer: I.E. Medica, Inc.
DRP-7926-02
Sep 2, 2031
FeMaxIron (as Iron Sucrose)
20 mg/mL Solution for Injection (IV)USP Type I Clear Glass Ampoule x 5 mL in a Plastic Tray x 5's (Box of 5's)
Rx
Gulf Pharmaceutical Industries (Julphar)United Arab Emirates
DéGa International Pharma Corp.
DR-XY43848
Oct 30, 2029
FemorumIron Sucrose
20 mg/mL (100 mg/5 mL) Solution for IV InjectionUSP Type I Colorless Transparent Glass Ampoule x 5 mL (Box of 5's)
Rx
Myungmoon Pharmaceutical Co., Ltd.Republic of Korea
Central West Medicale Inc.Importer: H & B Pharma International Inc.
DR-XY43638
Aug 18, 2029
FenemikIron [as Ferric hydroxide sucrose complex]
20 mg/mL (100 mg/5 mL) Concentrate for Solution for Injection (I.V. Infusion)5 mL amber-colored glass ampoule Type I (Box of 5's)
Rx
Mefar Ilac Sanayii A.S.Turkey
Ambica International CorporationTrader: Pharmada Ilac San. Ve Tic. A.S.
DRP-10294
Sep 6, 2030
FeravinIron Sucrose
20 mg/mL Solution for Intravenous (I.V.) InjectionUSP Type I Amber Glass Ampoule x 5 mL (Box of 5's)
Rx
Mason PharmaIndia
MDB Pharma TradingImporter: Finstad Inc.
DRP-12662-01
Sep 20, 2027
FerogenIron Sucrose
20 mg/mL ( 100 mg/5 mL) Solution for Injection (I.V.)USP Type I Amber Glass Ampoule x 5 mL Box of 1 's
Rx
Samarth Life Sciences Pvt. Ltd.India
NEXT CHEMICAL ENTERPRISES
DRP-6412
Feb 28, 2029
FeronIron (as sucrose)
20 mg/mL (100 mg/5 mL) Solution for I.V. Injection5 mL USP Type I Amber Glass Ampoule (Box of 5's)
Rx
Gland Pharma LimitedIndia
Endure Medical, Inc.
DR-XY37826
Apr 23, 2027
FeroseaIron Sucrose (as Ferric Hydroxide Sucrose Complex)
20 mg/mL (100 mg/5 mL) Solution for IV Injection5 mL USP Type I Amber Glass Ampoule (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
Seapharma International, Inc.
DRP-14640
Nov 9, 2028
FeroxIron Sucrose (As Ferric Hydroxide Sucrose Complex)
20 mg/mL (100 mg/5ml) Solution For Injection (IV)5 mL Type I Amber Glass Ampoule (Box of 5's)
Rx
Med Biopharm Pvt. Ltd.India
Euroasia Pharmaceuticals, Inc.Importer: Pors Pharma Trading
DRP-16628-01
Sep 12, 2028
FerriscriptIron (as Iron Sucrose)
100 mg/5 mL Solution for Injection (I.V.)USP Type I Amber Glass Ampoule x 5 mL (Box of 1 PVC Tray x 5's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Scriptmed, Inc.Importer: Ambica International Corporation
DRP-7844-05
Jan 26, 2028
FerriscriptIron (as Ferric Hydroxide Sucrose Complex)
20mg/mL (100mg/5mL) Solution for Injection (I.V.)USP Type I amber glass ampoule x 5mL in a plastic tray (Box of 5's)
Rx
Alwin DMD PharmaceuticalsIndia
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-7111-02
Mar 17, 2027
FerroferIron Sucrose
20 mg/mL Solution for Injection (IV)Amber glass ampoule x 5 mL (Box of 5's)
Rx
Nanjing Hencer Pharmaceutical Co., Ltd.China
Goodfellow Pharma Corporation
DR-XY34774
Aug 6, 2030
FerronfreeIron (as Ferric Hydroxide Sucrose Complex)
20mg/mL (100mg/5mL) Solution for Injection (I.V.)5 mL USP Type I Amber Glass Ampoule (Box of 5's)
Rx
Alwin DMD PharmaceuticalsIndia
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-7111-09
Mar 17, 2027
FersucrosIron (as Iron Sucrose)
100 mg/5 mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 5's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Diafarm Inc.Importer: Ambica International Corporation
DRP-7844-03
Jan 26, 2028
FerumcroseIron (as Iron Sucrose)
100 mg/5 mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 5's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Multi Product Line Pharma, Inc.Importer: Ambica International Corporation
DRP-7844-04
Jan 26, 2028
FeruvinIron (As Iron Sucrose)
20 mg/mL (100mg/5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
Vintel Med EnterprisesImporter: Afree Pharmaceutical Distribution Corp.
DRP-13888-02
May 11, 2028
FeruvinIron (as Ferric Hydroxide Sucrose Complex)
20 mg/mL (100mg/5mL) Solution for Injection (IV)5mL USP Type I amber glass ampoule (Box of 5 ampoules in plastic tray)
Rx
Alwin DMD PharmaceuticalsIndia
Vintel Med EnterprisesImporter: Bliss Pharma Distribution and Consultancy Corp.
DRP-7111-01
Mar 17, 2027
FridaIron Sucrose
20 mg/mL Solution For Injection (IV)Usp Type I Clear Glass Ampoule By 5 Ml (Box Of 5'S, 10'S And 25'S)
Rx
Baxter Pharmaceuticals India Private LimitedIndia
UNILAB, Inc.Importer: Baxter Healthcare Philippines, Inc.
DRP-2437-02
Nov 11, 2027
HEMOSUCROIron Sucrose (as Ferric Hydroxide Sucrose Complex)
20 mg/mL Solution for Injection (IV)5 mL USP Type I Clear Fiolax Glass Ampoule (Box of 5's)
Rx
Farbe FirmaIndia
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-16452-02
Mar 14, 2030
HeronseIron (as Iron sucrose)
20 mg/mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 5’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III - Injectables)India
Asterzenmed Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Limited
DRP-10887
Dec 29, 2031
IfervestIron (as Iron Sucrose)
20 mg/mL Solution for Injection (I.V.)Type I amber glass ampoule x 5 mL in a PVC plastic tray (Box of 5’s)
Rx
Kamla Lifesciences LtdIndia
Ambica International CorporationTrader: Omnicals Pharma Private Limited
DRP-18933
Oct 13, 2031
InofarIron Sucrose (Iron III Hydroxide Sucrose Complex)
20 mg/mL (100 mg/5mL) Solution for Intravenous InfusionUSP Type I Glass Amber Ampoule x 5mL (Box of 2 ampoules)
Rx
Aristopharma Ltd.Bangladesh
Sahar International Trading, Inc.
DRP-4634
Dec 19, 2027
IroferIron (as Ferric Hydroxide Sucrose Complex)
20mg/mL (100mg/5mL) Solution for Injection (IV)5 mL USP Type I amber glass ampoule (Box of 5 ampoules in plastic tray)
Rx
Alwin DMD PharmaceuticalsIndia
Genace Pharma DistributorImporter: Bliss Pharma Distribution and Consultancy Corp.
DRP-7111-06
Mar 17, 2027
IroferoseIron (as Iron Sucrose)
100 mg/5 mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 1 PVC Tray x 5's)
Rx
Swiss Parenterals Ltd.India
New Marketlink Pharmaceutical CorporationImporter: Ambica International Corporation
DRP-7844-01
Jan 26, 2028
IrofreeIron (as Ferric Hydroxide Sucrose Complex)
20 mg/mL (100mg/5mL) Solution for Injection (IV)5mL USP Type I Amber glass ampoule (Box of 5's in plastic tray)
Rx
Alwin DMD PharmaceuticalsIndia
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-7111-07
Mar 17, 2027
IromaxIron (as Iron Sucrose)
20mg/mL Solution For Injection (IV)Type I Glass Ampoule x 5mL (Box of 5's in a plastic tray)
Rx
MAXITECH PHARMA (PVT) LTD.Pakistan
Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc.
DRP-14215
Jul 27, 2028
IronexIron (as Iron Sucrose)
20 mg / mL Solution for Injection (IV)5 mL USP Type I glass ampoule in PVC tray x 5's (Box of 5’s)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-16053-01
Dec 10, 2029
IronovaIron Sucrose (as Ferric Hydroxide Sucrose Complex)
20 mg/mL Solution for Injection (IV)5 mL USP Type I Clear Fiolax Glass Ampoule (Box of 5's)
Rx
Farbe FirmaIndia
Medinova Pharmaceutical Inc.
DRP-16452
Mar 14, 2030
IronsaveIron (as Iron Sucrose)
20 mg/mL solution for injection (IV)Type I Glass Ampoule x 5 mL (Box of 5's in a plastic tray)
Rx
Maxitech Pharma (Pvt) Ltd.Pakistan
Savelink Pharma And Trading CoImporter: Accesspoint International Trading Inc.
DRP-14215-01
Jul 27, 2028
IronseIron (as Iron sucrose)
20 mg/mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 5 mL (Box of 5’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III - Injectables)India
CDM Marketing CenterImporter: Ambica International CorporationTrader: Unosource Pharma Limited
DRP-10886
Dec 29, 2031
IrophilIron (as Iron sucrose)
100 mg/5 mL Solution for Injection (I.V.)USP Type I amber glass ampoule x 5 mL in a plastic tray (Box of 5's)
Rx
Ratnaris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-17550
Jan 26, 2031
IroxariIron Sucrose (as Ferric Hydroxide Sucrose Complex)
20 mg/mL (100 mg/5 mL) Solution for I.V. InjectionType I Amber colored glass ampoule x 5 mL (Box of 5's)
Rx
Pharmax India Private LimitedIndia
Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd.
DRP-15313
Jul 2, 2029
IrsucIron (as Ferric Hydroxide Sucrose Complex)
20 mg / mL (100 mg / 5 mL) Solution for Injection (IV)5 mL Amber Glass Ampoule (Box of 5’s)
Rx
Zee Laboratories LimitedHimachal Pradesh India
One Pharma Marketing Inc.Importer: Eon Pharmatek Inc.
DRP-15056-01
Oct 5, 2027
IRSUCIron (as Iron Sucrose)
20 mg/mL (100mg/5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
One Pharma Marketing Inc.Importer: Afree Pharmaceutical Distribution Corp.
DRP-13888-07
May 11, 2028
IrsucIron (as Ferric Hydroxide Sucrose Complex)
20 mg/mL (100mg/5mL) Solution for Injection (IV)5 mL USP Type I Amber glass ampoule (Box of 5's)
Rx
Alwin DMD PharmaceuticalsIndia
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-7111-08
Mar 17, 2027
IseronIron Sucrose
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)5 mL USP Type I Amber Glass Ampoule (Box of 5's)
Rx
Swiss Parenterals Ltd.India
Endure Medical, Inc.
DR-XY42932
Nov 13, 2028
IsucrinIron Sucrose
20 mg/mL Solution for Intravenous (I.V.) InjectionUSP Type I Amber Glass Ampoule x 5 mL (Box of 5’s)
Rx
Mason PharmaIndia
Ellebasy Medicale Group Inc.Importer: Finstad Inc.
DRP-12662-03
Sep 20, 2027
IsuferIron (as Iron Sucrose)
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
GPC Geo Pharma CorporationImporter: Afree Pharmaceutical Distribution Corp.
DRP-13888-04
May 11, 2028
IsuferIron (as Ferric Hydroxide Sucrose Complex)
20 mg/mL (100mg/5mL) Solution for Injection (IV)5mL USP Type I amber glass ampoule (Box of 5 ampoules in plastic tray)
Rx
Alwin DMD PharmaceuticalsIndia
GPC Geo Pharma CorporationImporter: Bliss Pharma Distribution and Consultancy Corp.
DRP-7111-03
Mar 17, 2027
MaxiferIron Sucrose
20 mg/mL (100mg/5mL) Solution for Injection (IV)USP Type I clear colorless glass ampoule x 5 mL (Box of 5's)
Rx
Gland Pharma PrivateIndia
Multicare Pharmaceuticals Philippines, Inc.Importer: Biocare Lifesciences, Inc.
DRP-5540-02
May 6, 2031
MedoferIron sucrose
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I Clear Glass Ampoule x 5 mL m a Clear PVC Plastic Tray x 5 's (Box of 5' s)
Rx
Samrudh Pharmaceuticals Pvt. Ltd.India
Helande Kidney Care lnc.Importer: I.E. Medica, Inc.
DRP-7926
Sep 2, 2031
MesoferIron Sucrose
20mg/mL Solution for Intravenous (I.V.) Injection5 ml Amber USP Type-I Glass Ampoules (Box of 5's)
Rx
Mason PharmaIndia
Finstad, Inc.
DRP-12662
Sep 20, 2027
NoneIron (as Iron Sucrose)
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
One Pharma Marketing Inc.Importer: Afree Pharmaceutical Distribution Corp.
DRP-13888-05
May 11, 2028
NoneIron (as Iron Sucrose)
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I Amber Glass ampoule in PVC plastic tray x 5 mL (Box of 5's)
Rx
Makcur laboratories LimitedIndia
Medinova Pharmaceutical Inc.Importer: Afree Pharmaceutical Distribution Corp.
DRP-13888-06
May 11, 2028
NoneIron (as Iron Sucrose)
20 mg/mL (100mg/5 mL) Solution for Injection (IV)USP Type I Amber Glass ampoule in PVC Plastic tray x 5 mL (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
Genace Pharma DistributorImporter: Afree Pharmaceutical Distribution Corp.
DRP-13888-01
May 11, 2028
NoneIron (as Iron sucrose)
20 mg/mL Solution for Injection (IV)Type I Glass Ampoule x 5mL (Box of 5's in a plastic tray)
Rx
Maxitech Pharma (Pvt.) Ltd.Pakistan
Rexmed Pharmaceutical SalesImporter: Accesspoint International Trading Inc.
DRP-14215-02
Jul 27, 2028
NoneIron (as Iron sucrose)
20 mg/mL Solution for Injection (IV)Type I Glass Ampoule x 5mL (Box of 5's in plastic tray)
Rx
Maxitech Pharma (Pvt.) Ltd.Pakistan
Reta DrugImporter: Accesspoint International Trading Inc.
DRP-14215-04
Jul 27, 2028
PorsroseIron Sucrose (as Ferric Hydroxide Sucrose Complex)
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)5 mL Type I Amber Glass Ampoule (Box of 5's)
Rx
Med Biopharm Pvt. Ltd.India
Pors Pharma Trading
DR-XY48874
Sep 12, 2028
PorsroseIron Sucrose (As Ferric Hydroxide Sucrose Complex)
20 mg/mL(100 Mg/5ml) Solution For Injection (Iv)5 mL Type I Amber Glass Ampoule (Box of 5's)
Rx
Med Biopharm Pvt. Ltd.India
Pors Pharma Trading
DRP-16628
Sep 12, 2028
RanoferIron (As Iron Sucrose)
20 mg/mL (100mg/5 mL) Solution for Injection (I.V.)5 mL Type I Amber glass ampoules (Box of 5's)
Rx
Duopharma (M) Sdn. Bhd.Malaysia
DB (Philippines), Inc.
DR-XY48113
Jun 17, 2027
RetaroneIron (as Iron Sucrose)
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)USP Type I amber glass ampoule in PVC plastic tray x 5 mL (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
Reta DrugImporter: Afree Pharmaceutical Distribution Corp.
DRP-13888-08
May 11, 2028
SaluFerIron Sucrose
20 mg/mL Solution for Intravenous (I.V.) InjectionUSP Type I, Amber Glass Ampoule x 5 mL (Box of 5's)
Rx
Mason PharmaIndia
Salusa Medical Supplies And Pharmaceuticals Inc.Importer: Finstad Inc.
DRP-12662-02
Sep 20, 2027
SironIron Sucrose
20 mg/mL Solution for Intravenous (I.V.) InjectionUSP Type I Amber Glass Ampoule x 5 mL (Box of 5's)
Rx
Mason PharmaIndia
JL Dialmed Trading Co.Importer: Finstad, Inc.
DRP-12662-04
Sep 20, 2027
SucroferIron Sucrose
20 mg/mL Solution For Injection (IV)Usp Type I Clear Glass Ampoule By 5 Ml (Box Of 5'S, 10'S And 25'S)
Rx
Baxter Pharmaceuticals India Private LimitedIndia
Importer: Baxter Healthcare Philippines, Inc.
DRP-2437
Nov 11, 2027
SucronavIron Sucrose (as Ferric Hydroxide Sucrose Complex)
20 mg/mL Solution for Injection (IV)5 mL USP Type I Clear Fiolax Glass Ampoule (Box of 5's)
Rx
Farbe FirmaIndia
JN Carlo Pharmaceuticals DistributorImporter: Medinova Pharmaceutical Inc.
DRP-16452-01
Mar 14, 2030
SucrosaphIron (as Iron Sucrose)
20 mg/mL (100 mg/5 mL) Solution for Injection (I.V.)Type I Amber Glass Ampoule x 5 mL (Box of 5's)
Rx
Kilitch Drug (India) Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences, Pvt. Ltd.
DRP-13241
Dec 11, 2030
SucrostarIron (as iron sucrose)
20 mg/mL Solution for Injection (I.V.)Amber Ampoule
Rx
Aculife Healthcare Private LimitedIndia
Blue Global (FZE)
DRP-15679
Aug 20, 2029
SucruferIron (as Iron sucrose)
20 mg/mL Solution for Injection (IV)Type I Glass Ampoule x 5mL (Box of 5's in a plastic tray)
Rx
Maxitech Pharma (Pvt.) Ltd.Pakistan
FERJAN PHILIPPINES INC.Importer: Accesspoint International Trading Inc.
DRP-14215-03
Jul 27, 2028
SurconIron Sucrose (as Ferric Hydroxide Sucrose Complex)
20 mg/mL (100 mg/5 mL) Solution for Injection (IV)5 mL USP Type I Amber Glass Ampoule in a PVC Tray x 5's (Box of 5's)
Rx
Makcur Laboratories LimitedIndia
Pharma-Surrey International Inc.
DRP-16391
Feb 26, 2030
VenroseIron [as Ferric hydroxide sucrose complex]
20 mg/mL (100 mg/5 mL) Concentrate for Solution for Injection (I.V. Infusion)5 mL Type I amber glass ampoule (Box of 5's)
Rx
Mefar Ilac Sanayii A.S.Turkey
Ambica International CorporationTrader: Pharmada Ilac San. Ve Tic. A.S.
DRP-10297
Sep 9, 2031
Zypiron 20Iron (as Ferric hydroxide sucrose complex)
20 mg/mL (100 mg/5 mL) Lyophilized Powder For Injection (Iv)5 mL Clear USP Type I moulded glass vial (Box of 5's ); Box of 5's as Physician's sample
Rx
Cadila Healthcare LimitedIndia
Zydus Healthcare Philippines Inc.
DRP-11619
Apr 4, 2027
(no brand name)Iron Sucrose
363.64 mg/mL (equivalent to 20 mg elemental Iron) Solution for Injection (I.V.)USP Type I flint moulded glass vial with 20 mm grey bromobutyl rubber stopper closure and 20 mm light blue flip-off aluminum seal x 5 mL and 10 mL (Box of l's)
Rx
Mylan Laboratories Limited (Hosur Sterile Facility)India
Mylan Philippines Inc.
DRP-11142
Feb 7, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Injection: 100 mg/5 mL (20 mg/mL) in single-dose vials. (3) Injection: 100 mg/5 mL (20 mg/mL) in single-dose vials.

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Hypersensitivity Reactions: Observe for signs and symptoms of hypersensitivity during and after Venofer administration for at least 30 minutes and until clinically stable following completion of each administration. Only administer Venofer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. (5.1)
  • Hypotension: May cause hypotension. Monitor for signs and symptoms of hypotension during and following each administration. (5.2)
  • Iron Overload: Regularly monitor hematologic responses during therapy. Do not administer to patients with iron overload. (5.3)
5.1 Hypersensitivity Reactions

5.1 Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Venofer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. If hypersensitivity reactions or signs of intolerance occur during administration, stop Venofer immediately.

Monitor patients for signs and symptoms of hypersensitivity during and after Venofer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Venofer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.

Most reactions associated with intravenous iron preparations occur within 30 minutes of the completion of the infusion [see Adverse Reactions (6.1 and 6.2)].

5.2 Hypotension

5.2 Hypotension Venofer may cause clinically significant hypotension. Monitor for signs and symptoms of hypotension following each administration of Venofer. Hypotension following administration of Venofer may be related to the rate of administration and/or total dose administered [see Dosage and Administration (2), Warnings and Precautions (5.1), and Adverse Reactions (6.2)].

5.3 Iron Overload

5.3 Iron Overload Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. All adult and pediatric patients receiving Venofer require periodic monitoring of hematologic and iron parameters (hemoglobin, hematocrit, serum ferritin and transferrin saturation).

Do not administer Venofer to patients with evidence of iron overload. Transferrin saturation (TSAT) values increase rapidly after intravenous administration of iron sucrose; do not perform serum iron measurements for at least 48 hours after intravenous dosing [see Dosage and Administration (2) and Overdosage (10)].

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Venofer may reduce the absorption of concomitantly administered oral iron preparations.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Hypotension [see Warnings and Precautions (5.2)] Iron Overload [see Warnings and Precautions (5.3)] Adult patients: The most common adverse reactions (≥2%) are diarrhea, nausea, vomiting, headache, dizziness, hypotension, pruritus, pain in extremity, arthralgia, back pain, muscle cramp, injection site reactions, chest pain, and peripheral edema. (6.1)
  • Pediatric patients: The most common adverse reactions (≥2%) are headache, respiratory tract viral infection, peritonitis, vomiting, pyrexia, dizziness, cough, nausea, arteriovenous fistula thrombosis, hypotension, and hypertension. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact American Regent, Inc. at 1-800-734-9236 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Adverse Reactions in Clinical Trials

6.1 Adverse Reactions in Clinical Trials Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug may not reflect the rates observed in practice. Adverse Reactions in Adults Patients with CKD The frequency of adverse reactions associated with the use of Venofer has been documented in six clinical trials involving 231 patients with HDD-CKD, 139 patients with NDD-CKD and 75 patients with PDD-CKD.

Adverse reactions reported by ≥ 2% of treated patients in the six clinical trials for which the rate for Venofer exceeds the rate for comparator are listed by indication in Table 1. Patients with HDD-CKD received 100 mg doses at 10 consecutive dialysis sessions until a cumulative dose of 1000 mg was administered. Patients with NDD-CKD received either 5 doses of 200 mg over 2 weeks or 2 doses of 500 mg separated by fourteen days, and patients with PDD-CKD received 2 doses of 300 mg followed by a dose of 400 mg over a period of 4 weeks.

Table 1. Adverse Reactions Reported in ≥ 2% of Study Populations and for which the Rate for Venofer Exceeds the Rate for Comparator * EPO=Erythropoietin Body System/Adverse Reactions HDD-CKD NDD-CKD PDD-CKD Venofer Venofer Oral Iron Venofer EPO* Only (N=231) (N=139) (N=139) (N=75) (N=46) % % % % % Subjects with any adverse reaction 78.8 76.3 73.4 72.0 65.2 Ear and Labyrinth Disorders Ear Pain 0 2.2 0.7 0 0 Eye Disorders Conjunctivitis 0.4 0 0 2.7 0 Gastrointestinal Disorders Abdominal pain 3.5 1.4 2.9 4.0

6.5 Diarrhea 5

6.5 Diarrhea 5.2 7.2 10.1 8.0 4.3 Dysgeusia 0.9 7.9 0 0 0 Nausea 14.7 8.6 12.2 5.3 4.3 Vomiting 9.1 5.0 8.6 8.0 2.2 General Disorders and Administration Site Conditions Asthenia 2.2 0.7 2.2 2.7 0 Chest pain 6.1 1.4 0 2.7 0 Feeling abnormal 3.0 0 0 0 0 Infusion site pain or burning 0 5.8 0 0 0 Injection site extravasation 0 2.2 0 0 0 Peripheral edema 2.6 7.2 5.0 5.3 10.9 Pyrexia 3.0 0.7 0.7 1.3 0 Infections and Infestations Nasopharyngitis, Sinusitis, Upper respiratory tract infections, Pharyngitis 2.6 2.2 4.3 16.0 4.3 Injury, Poisoning and Procedural Complications Graft complication 9.5 1.4 0 0 0 Metabolism and Nutrition Disorders Fluid overload 3.0 1.4 0.7 1.3 0 Gout 0 2.9 1.4 0 0 Hyperglycemia 0 2.9 0 0 2.2 Hypoglycemia 0.4 0.7 0.7 4.0 0 Musculoskeletal and Connective Tissue Disorders Arthralgia 3.5 1.4 2.2 4.0 4.3 Back pain 2.2 2.2 3.6 1.3 4.3 Muscle cramp 29.4 0.7 0.7 2.7 0 Myalgia 0 3.6 0 1.3 0 Pain in extremity 5.6 4.3 0 2.7

6.5 Nervous System Disorders Dizziness 6

6.5 Nervous System Disorders Dizziness 6.5 6.5 1.4 1.3 4.3 Headache 12.6 2.9 0.7 4.0 0 Respiratory, Thoracic and Mediastinal Disorders Cough 3.0 2.2 0.7 1.3 0 Dyspnea 3.5 5.8 1.4 1.3 2.2 Nasal congestion 0 1.4 2.2 1.3 0 Skin and Subcutaneous Tissue Disorders Pruritus 3.9 2.2 4.3 2.7 0 Vascular Disorders Hypertension 6.5 6.5 4.3 8.0

6.5 Hypotension 39

6.5 Hypotension 39.4 2.2 0.7 2.7 2.2 One hundred thirty (11%) of the 1,151 patients evaluated in the 4 U.S. trials in HDD-CKD patients (studies A, B and the two post marketing studies) had prior other intravenous iron therapy and were reported to be intolerant (defined as precluding further use of that iron product). When these patients were treated with Venofer there were no occurrences of adverse reactions that precluded further use of Venofer [see Warning and Precautions (5)].

Adverse Reactions in Pediatric Patients with CKD (ages 2 years and older) In a randomized, open-label, dose-ranging trial for iron maintenance treatment with Venofer in pediatric patients with CKD on stable erythropoietin therapy [see Clinical Studies (14.7)], at least one adverse reaction was experienced by 57% (27/47) of the patients receiving Venofer 0.5 mg/kg, 53% (25/47) of the patients receiving Venofer 1 mg/kg, and 55% (26/47) of the patients receiving Venofer 2 mg/kg. A total of 5 (11%) subjects in the Venofer 0.5 mg/kg group, 10 (21%) patients in the Venofer 1 mg/kg group, and 10 (21%) patients in the Venofer 2 mg/kg group experienced at least 1 serious adverse reaction during the study.

The most common adverse reactions (>2% of patients) in all patients were headache (6%), respiratory tract viral infection (4%), peritonitis (4%), vomiting (4%), pyrexia (4%), dizziness (4%), cough (4%), nausea (3%), arteriovenous fistula thrombosis (2%), hypotension (2%), and hypertension (2.1%).

6.2 Adverse Reactions from Post-Marketing Experience

6.2 Adverse Reactions from Post-Marketing Experience The following adverse reactions have been identified during post-approval use of Venofer. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

In the post-marketing safety studies in 1,051 treated patients with HDD-CKD, the adverse reactions reported by >1% were cardiac failure congestive, sepsis and dysgeusia. Immune system disorders: anaphylactic-type reactions, angioedema Psychiatric disorders: confusion Nervous system disorders: convulsions, collapse, light-headedness, loss-of-consciousness Cardiovascular System: bradycardia, shock, acute myocardial ischemia with or without myocardial infarction or with in-stent thrombosis in the context of a hypersensitivity reaction.

Respiratory, thoracic and mediastinal disorders: bronchospasm, dyspnea Musculoskeletal and connective tissue disorders: back pain, swelling of the joints Renal and urinary disorders: chromaturia General disorders and administration site conditions: hyperhidrosis Symptoms associated with Venofer total dosage or infusing too rapidly included hypotension, dyspnea, headache, vomiting, nausea, dizziness, joint aches, paresthesia, abdominal and muscle pain, edema, and cardiovascular collapse. These adverse reactions have occurred up to 30 minutes after the administration of Venofer injection.

Reactions have occurred following the first dose or subsequent doses of Venofer. Symptoms may respond to intravenous fluids, hydrocortisone, and/or antihistamines. Slowing the infusion rate may alleviate symptoms. Injection site discoloration has been reported following extravasation. Assure stable intravenous access to avoid extravasation.

Adverse reaction frequency tables (US label) US FDA label
Table 1. Adverse Reactions Reported in ≥ 2% of Study Populations and for which the Rate for Venofer Exceeds the Rate for Comparator
* EPO=Erythropoietin
Body System/Adverse Reactions HDD-CKD NDD-CKD PDD-CKD
Venofer Venofer Oral Iron Venofer EPO* Only
(N=231) (N=139) (N=139) (N=75) (N=46)
% % % % %
Subjects with any adverse reaction 78.8 76.3 73.4 72.0 65.2
Ear and Labyrinth Disorders
Ear Pain 0 2.2 0.7 0 0
Eye Disorders
Conjunctivitis 0.4 0 0 2.7 0
Gastrointestinal Disorders
Abdominal pain 3.5 1.4 2.9 4.0 6.5
Diarrhea 5.2 7.2 10.1 8.0 4.3
Dysgeusia 0.9 7.9 0 0 0
Nausea 14.7 8.6 12.2 5.3 4.3
Vomiting 9.1 5.0 8.6 8.0 2.2
General Disorders and
Administration Site Conditions
Asthenia 2.2 0.7 2.2 2.7 0
Chest pain 6.1 1.4 0 2.7 0
Feeling abnormal 3.0 0 0 0 0
Infusion site pain or burning 0 5.8 0 0 0
Injection site extravasation 0 2.2 0 0 0
Peripheral edema 2.6 7.2 5.0 5.3 10.9
Pyrexia 3.0 0.7 0.7 1.3 0
Infections and Infestations
Nasopharyngitis, Sinusitis, Upper respiratory tract infections, Pharyngitis 2.6 2.2 4.3 16.0 4.3
Injury, Poisoning and Procedural
Complications
Graft complication 9.5 1.4 0 0 0
Metabolism and Nutrition Disorders
Fluid overload 3.0 1.4 0.7 1.3 0
Gout 0 2.9 1.4 0 0
Hyperglycemia 0 2.9 0 0 2.2
Hypoglycemia 0.4 0.7 0.7 4.0 0
Musculoskeletal and Connective
Tissue Disorders
Arthralgia 3.5 1.4 2.2 4.0 4.3
Back pain 2.2 2.2 3.6 1.3 4.3
Muscle cramp 29.4 0.7 0.7 2.7 0
Myalgia 0 3.6 0 1.3 0
Pain in extremity 5.6 4.3 0 2.7 6.5
Nervous System Disorders
Dizziness 6.5 6.5 1.4 1.3 4.3
Headache 12.6 2.9 0.7 4.0 0
Respiratory, Thoracic and
Mediastinal Disorders
Cough 3.0 2.2 0.7 1.3 0
Dyspnea 3.5 5.8 1.4 1.3 2.2
Nasal congestion 0 1.4 2.2 1.3 0
Skin and Subcutaneous
Tissue Disorders
Pruritus 3.9 2.2 4.3 2.7 0
Vascular Disorders
Hypertension 6.5 6.5 4.3 8.0 6.5
Hypotension 39.4 2.2 0.7 2.7 2.2

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Published studies on intravenous iron sucrose treatment after the first trimester of pregnancy have not shown adverse maternal or fetal outcomes (see Data). Available reports of intravenous iron sucrose use in pregnant women during the first trimester are insufficient to assess the risk of major birth defects and miscarriage.

There are risks to the mother and fetus associated with untreated IDA in pregnancy as well as risks to the fetus associated with maternal severe hypersensitivity reactions (see Clinical Considerations). Animal reproduction studies of iron sucrose administered to rats and rabbits during the period of organogenesis at elemental iron doses equivalent to the maximum recommended human dose based on body surface area revealed no evidence of harm to the fetus (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically-recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Iron deficiency anemia during pregnancy should be treated. Untreated IDA in pregnancy is associated with adverse maternal outcomes such as post-partum anemia. Adverse pregnancy outcomes associated with IDA include increased risk for preterm delivery and low birth weight.

Fetal/Neonatal adverse reactions Severe adverse reactions including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction) may occur in pregnant women with parenteral iron products (such as Venofer) which may cause fetal bradycardia, especially during the second and third trimester. Data Human Data Published data from randomized controlled studies and prospective observational studies on the use of Venofer in pregnant women have not reported an association of Venofer and adverse developmental outcomes.

However, these studies did not include women exposed during the first trimester of pregnancy and were not designed to assess the risk of major birth defects. Maternal adverse events reported in these studies are similar to those reported during clinical trials in adult males and non-pregnant females [see Adverse Reactions (6.1)].

Animal Data Iron sucrose was administered intravenously to rats and rabbits during the period of organogenesis at elemental iron doses up to 13 mg/kg/day (0.25 times or equivalent to the maximum recommended human dose based on body surface area, respectively) and revealed no evidence of harm to the fetus.

Mechanism of action

12.1 Mechanism of Action Venofer is an aqueous complex of poly-nuclear iron (III)-hydroxide in sucrose. Following intravenous administration, Venofer is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron in the precursor cells is incorporated into hemoglobin as the cells mature into red blood cells.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Following intravenous administration, Venofer is dissociated into iron and sucrose. In 22 patients undergoing hemodialysis and receiving erythropoietin (recombinant human erythropoietin) therapy treated with iron sucrose containing 100 mg of iron, three times weekly for three weeks, significant increases in serum iron and serum ferritin and significant decreases in total iron binding capacity occurred four weeks from the initiation of iron sucrose treatment.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

12.3 Pharmacokinetics In healthy adults administered intravenous doses of Venofer, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L.

The sucrose component is eliminated mainly by urinary excretion.

In a study evaluating a single intravenous dose of Venofer containing 1,510 mg of sucrose and 100 mg of iron in 12 healthy adults (9 female, 3 male: age range 32 to 52), 68.3% of the sucrose was eliminated in urine in 4 h and 75.4% in 24 h.

Some iron was also eliminated in the urine.

In this study and another study evaluating a single intravenous dose of iron sucrose containing 500 to 700 mg of iron in 26 patients with anemia on erythropoietin therapy (23 female, 3 male; age range 16 to 60), approximately 5% of the iron was eliminated in urine in 24 h at each dose level.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics In healthy adults administered intravenous doses of Venofer, its iron component exhibited first order kinetics with an elimination half-life of 6 h, total clearance of 1.2 L/h, and steady state apparent volume of distribution of 7.9 L. The iron component appeared to distribute mainly in blood and to some extent in extravascular fluid.

A study evaluating Venofer containing 100 mg of iron labeled with 52 Fe/ 59 Fe in patients with iron deficiency showed that a significant amount of the administered iron is distributed to the liver, spleen and bone marrow and that the bone marrow is an irreversible iron trapping compartment. Following intravenous administration of Venofer, iron sucrose is dissociated into iron and sucrose.

The sucrose component is eliminated mainly by urinary excretion. In a study evaluating a single intravenous dose of Venofer containing 1,510 mg of sucrose and 100 mg of iron in 12 healthy adults (9 female, 3 male: age range 32 to 52), 68.3% of the sucrose was eliminated in urine in 4 h and 75.4% in 24 h. Some iron was also eliminated in the urine.

Neither transferrin nor transferrin receptor levels changed immediately after the dose administration. In this study and another study evaluating a single intravenous dose of iron sucrose containing 500 to 700 mg of iron in 26 patients with anemia on erythropoietin therapy (23 female, 3 male; age range 16 to 60), approximately 5% of the iron was eliminated in urine in 24 h at each dose level.

The effects of age and gender on the pharmacokinetics of Venofer have not been studied. Pharmacokinetics in Pediatric Patients In a single-dose PK study of Venofer, patients with NDD-CKD ages 12 to 16 (N=11) received intravenous bolus doses of Venofer at 7 mg/kg (maximum 200 mg) administered over 5 minutes. Following a single dose of Venofer, the half-life of total serum iron was 8 hours.

The mean Cmax and AUC values were 8545 μg/dl and 31305 hr•μg/dL, respectively, which were 1.42- and 1.67-fold higher than dose adjusted adult Cmax and AUC values. Venofer is not dialyzable through CA210 (Baxter) High Efficiency or Fresenius F80A High Flux dialysis membranes. In in vitro studies, the amount of iron sucrose in the dialysate fluid was below the levels of detection of the assay (less than 2 parts per million).

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Iron Sucrose 20 mg/mL, 5 mL Ampule₱85.10–₱288.00Reference ₱111.56per ampuleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Iron sucrose
PNF listingInj.: 20 mg/mL, 5 mL ampule
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Venofer · American Regent, Inc. [US FDA-approved label, version 12, March 1, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b998ef36-81fa-40a1-9cd1-6d6156f91564
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .